Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison Arm Clear all

Conditions: Arterial Disease
Interventions: Accuracy of the VitalDetect™ pulse oximetry system; Device
Lead sponsor: Vital USA, Inc.; Industry
Eligibility: 18 Years to 52 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Acute Coronary Syndrome, Depressive Symptoms
Interventions: Cognitive Behavioral Therapy (CBT), Antidepressant Medication, Standard Care, Depressive symptom screener, No intervention; Other · Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 1,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Bloomington, Minnesota • New York, New York • Henderson, North Carolina + 1 more

Conditions: Bacterial Infections
Interventions: Ciprofloxacin single dose, Ciprofloxacin triple dose; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 18
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more

Conditions: Healthy
Interventions: ABT-143, ABT-335, rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Volunteers
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • Grayslake, Illinois

Conditions: Narcolepsy Type 1, Narcolepsy Type 2
Interventions: cleminorexton, Placebo; Drug
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Brandon, Florida + 20 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Benralizumab, Placebo and Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more

Conditions: Obesity, Overweight, Type 2 Diabetes
Interventions: LY3549492, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 38
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Greenbrae, California + 33 more

Conditions: Glaucoma
Interventions: Trabeculectomy, Ex-PRESS mini shunt; Procedure · Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 7
States / cities: San Francisco, California • Gainesville, Florida • St Louis, Missouri + 4 more

Conditions: Opioid Consumption, Postoperative
Interventions: Suzetrigine, Standard Care (in control arm); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Breast Cancer
Interventions: Radiation therapy - 3 weeks, Radiation therapy - 2 weeks; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 90 Years · Female only
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: New York, New York

Conditions: PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography, Prostate Biopsy, Carcinoma of the Prostate
Interventions: 68Ga-PSMA-11; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Boca Raton, Florida + 13 more

Conditions: Hepatitis C Virus
Interventions: Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Telaprevir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 28
States / cities: Birmingham, Alabama • Anaheim, California • Garden Grove, California + 20 more

Conditions: Affective Disorders
Interventions: Ziprasidone, Sertraline, Haloperidol; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23); Biological
Lead sponsor: Rohit Divekar; Other
Eligibility: 19 Years to 20 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Surgery, Adolescent Behavior
Interventions: Behavioral Economics (BE) recruitment strategies, Biofeedback-based virtual reality (VR-BF), Manage My Pain; Behavioral · Other
Lead sponsor: Vanessa Olbrecht; Other
Eligibility: 12 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, placebo, sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more

Conditions: HIV Infections
Interventions: Stable CH505TF gp120, Transient CH505TF gp120, Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee

Conditions: Gonorrhea
Interventions: zoliflodacin, ceftriaxone, azithromycin; Drug
Lead sponsor: Global Antibiotics Research and Development Partnership; Other
Eligibility: 12 Years and older
Enrollment: 1,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 2 more

Conditions: Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Adderall-XR®, Concerta®; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 6 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 9
States / cities: Gainesville, Florida • Pensacola, Florida • Tampa, Florida + 4 more

Conditions: Cervical Cancers
Interventions: 3-Fraction HDR Brachytherapy, 4-Fraction HDR Brachytherapy; Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Developmental Delay
Interventions: Bright By Three (BB3), Texts for Child Safety (TCS); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Months to 15 Months
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Type 2
Interventions: Exenatide (AC2993), Insulin glargine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 21
States / cities: San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more

Conditions: Tumor Hyperinsulinism (Tumor HI)
Interventions: Ersodetug; Drug
Lead sponsor: Rezolute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more

Search by objective public record fields.

Vital USA SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry

Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

Prospective Randomized Study of Accelerated Radiation Therapy (PRART)

PSMA PET Combined With MRI for the Detection of PCa

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma

Recruitment and Behavioral Economic Strategies

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

Zoliflodacin in Uncomplicated Gonorrhoea

Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).

Bright by Three (BB3) Effectiveness Study

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism